Article Details

AstraZeneca to pay $30M upfront to license rare heart condition drug from Neurimmune

Retrieved on: 2022-03-01 09:49:21

Tags for this article:

Click the tags to see associated articles and topics

AstraZeneca to pay $30M upfront to license rare heart condition drug from Neurimmune. View article details on hiswai:

Excerpt

AstraZeneca's (AZN) Alexion will pay $30M upfront in an exclusive licensing agreement with Neurimmune AG for NI006, to treat a rare condition that ...

Article found on: seekingalpha.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up